Core Viewpoint - The chairman of New Mileage, Lin Yanglin, is under investigation by the Taiyuan Municipal Xiaodian District Supervisory Committee, which has led to his inability to perform his duties. The company stated that the matter is unrelated to its operations and has not been asked to assist in the investigation [1]. Group 1: Company Operations - New Mileage's main business segments include medical services and traditional Chinese medicine, with medical services accounting for approximately 80% of its revenue [2]. - In 2024, New Mileage reported a revenue of 3.799 billion yuan and a net profit attributable to shareholders of 115 million yuan [1]. - The company operates six regional medical centers across various provinces and has a total of 24 hospitals, including three tertiary hospitals and 14 secondary or higher-level hospitals [2]. Group 2: Corporate Structure and History - New Mileage's pharmaceutical business is primarily centered around the "Duyiwei" brand of traditional Chinese medicine, which contributes about 20% to its revenue [4]. - The company was formerly known as Hengkang Medical and became controlled by Beijing New Mileage Health Industry Group in 2022 [4]. - New Mileage Group manages over 40 hospitals across nearly 20 provinces, with a total bed capacity of 30,000, ranking among the top three in the country [4]. Group 3: Financial and Regulatory Issues - On June 20, Lin Yanglin and the CFO Liu Jun were subjected to regulatory discussions by the Gansu Securities Regulatory Bureau due to non-compliance with accounting standards related to stock incentive plans and construction project accounting [6]. - The financial discrepancies have led to inaccurate disclosures in the consolidated balance sheets for the fiscal years 2023 and the first three quarters of 2024, violating the regulations on information disclosure for listed companies [6].

2025.07. 07 本文字数：3412，阅读时长大约6分钟 作者 | 第一财经 吴斯旻 免学费、补助上万元、毕业后有编有岗、发房票……"公费医学生"在高考志愿填报阶段再度引起社会 关注，各地卫健委也纷纷拿出"真金白银"吸引医学预备人才回到家乡。 第一财经注意到，除了主要面向偏远农村招收的"公费医学生"，今年长三角部分经济发展水平较高的 市县地区也加入"抢人"队列。 由于不同地区医疗资源供给侧缺口存在差异，"公费医学生"的服务场景从农村乡镇卫生院延伸至城市 社区卫生服务中心和当地医院，资助对象需求也随之从面向"五年制本科"和"三年制专科"的农村订单 定向培养人才延伸至报考省内或全国重点高校的"拔尖人才"，从全科医学人才延伸至儿科、医学影像 学、重症医学等紧缺专业人才。 不过，无论是参与农村订单定向培养计划还是其他的政府资助计划，"公费医学生"通常均需要在毕业 后返回家乡工作满六年或更长的时间。那么，基层尤其是农村基层的临床工作、薪资待遇等，能够满 足定向医学生的需求吗？他们本科毕业后或工作期间，再深造的愿望能否被满足？高端医学人才在县 域地区能够匹配到合适的岗位吗？ 百强县送政策"大礼包"吸引高层次人才 近 ...

Group 1: Report Industry Investment Rating - No information provided Group 2: Core Viewpoints of the Report - On July 5th, the current-month contracts of the four major stock index futures showed mixed performance. IF rose 0.44%, IH rose 0.61%, IC fell 0.01%, and IM fell 0.29%. The total trading volume of stock index futures rebounded, indicating increased trading enthusiasm among investors. The trend intensities of IF and IH are 1, and those of IC and IM are also 1. There are important news including the resumption of product exports from the US to China and local measures for population development. The three major stock indices showed a pattern of rising and then falling [1][2][6] Group 3: Summary According to Related Catalogs 3.1 Stock Index Futures Data Tracking - **IF Contracts**: The closing prices of IF2507, IF2508, IF2509, and IF2512 all rose, with increases of 0.44%, 0.40%, 0.46%, and 0.47% respectively. The trading volumes and open interests of these contracts also increased. For example, the trading volume of IF2509 increased by 28,804, and the open interest increased by 14,488 [1] - **IH Contracts**: The closing prices of IH2507, IH2508, IH2509, and IH2512 all rose, with increases of 0.61%, 0.58%, 0.62%, and 0.59% respectively. The trading volumes and open interests also increased. For instance, the trading volume of IH2509 increased by 19,867, and the open interest increased by 9,229 [1] - **IC Contracts**: The closing prices of IC2507, IC2508, IC2509, and IC2512 all fell slightly, with decreases of 0.01%, 0.01%, 0.08%, and 0.04% respectively. The trading volumes and open interests increased. For example, the trading volume of IC2509 increased by 13,772, and the open interest increased by 6,230 [1] - **IM Contracts**: The closing prices of IM2507, IM2508, IM2509, and IM2512 all fell, with decreases of 0.29%, 0.36%, 0.43%, and 0.47% respectively. The trading volumes and open interests increased. For instance, the trading volume of IM2509 increased by 55,982, and the open interest increased by 16,019 [1] 3.2 Changes in the Top 20 Member Positions of Stock Index Futures - For most contracts, the long and short positions of the top 20 members showed increases. For example, in the IF2509 contract, the long positions increased by 11,728, and the short positions increased by 11,807 [5] 3.3 Important Driving Factors - There are reports that the US has resumed exports of products such as EDA software, ethane, and aircraft engines to China. Relevant departments in multiple regions are about to introduce measures for population development. The three major stock indices had a performance of rising and then falling, with some sectors showing strong performance and others weakening [6]

Group 1 - The article emphasizes the importance of "capacity reduction," which is reflected in the decline of capital expenditure, the abandonment of existing projects, and the guidance for the survival of the fittest among existing enterprises. This capacity reduction is a slow variable that will elevate the long-term profitability capability [3] - The current strong performance of the A-share market suggests a growing focus on long-term positive factors, although the current fundamental expectations and profit-making effects are not yet at bull market levels. The company's market outlook remains unchanged, predicting that 2026-27 will be the core period of the bull market, with signs of index improvement starting in Q4 2025 [3] - The article notes that the capital expenditure of internet platforms may improve, serving as a driving force for stock prices in the domestic AI computing power industry chain. In the short term, the market is highly focused on sectors such as electric equipment, steel, and building materials [3] Group 2 - Service consumption is recovering, with a notable expansion in the price decline of white liquor and pork. Year-on-year growth rates have been continuously rising since the beginning of the year [6]

Core Viewpoint - WeiMai Inc. (微脉) has submitted its prospectus for an IPO on the Hong Kong Stock Exchange, aiming to leverage AI in the healthcare sector to enhance service delivery and patient management [1][3]. Company Overview - WeiMai was established in 2013 and has undergone six rounds of financing and asset restructuring since its inception [1][3]. - The company focuses on connecting hospitals, doctors, and patients through AI technology, covering the entire health management process from pre-treatment to post-treatment [3]. - The registered capital of WeiMai is approximately 51.72 million RMB, with key shareholders including Qiu Jialin and Zhejiang Yuhang Transformation and Upgrade Industry Investment Co., Ltd. [3][4]. Financial History - WeiMai has completed several financing rounds, including: - A round of $6.75 million in 2016 - B round of $17.05 million in 2016 - B+ round of $27.3 million in 2018 - C round of approximately $57.13 million in 2019 - D round of $75 million in 2020 - D+ round of $5.175 million and 120 million RMB in 2023 [4][6]. - The pre-money valuation for the D+ round was approximately $559.25 million [4]. Revenue and Losses - WeiMai's revenue for 2022, 2023, and 2024 is projected to be approximately 512 million RMB, 628 million RMB, and 653 million RMB, respectively [10]. - Gross profit for the same years is estimated at around 88.23 million RMB, 118.3 million RMB, and 129.72 million RMB, with net losses of approximately 414.32 million RMB, 149.56 million RMB, and 193.11 million RMB [10]. - The adjusted net losses according to non-IFRS measures are projected to be about 233.26 million RMB, 99.11 million RMB, and 30.20 million RMB for the respective years [10]. Revenue Structure - The majority of WeiMai's revenue comes from full-course management and medical health product sales, contributing approximately 396 million RMB, 437 million RMB, and 470 million RMB, accounting for 77.3%, 69.7%, and 72.0% of total revenue [11].

Core Viewpoint - The chairman of New Mileage, Lin Yanglin, is under investigation, but the company asserts that the matter is unrelated to its operations and does not expect significant adverse effects on its business [2][4]. Group 1: Investigation and Management Changes - On July 6, New Mileage announced that its chairman Lin Yanglin was placed under investigation by the Taiyuan Municipal Supervision Committee, which has resulted in his inability to perform his duties [2]. - The company has appointed director Xu Minggui to temporarily fulfill the chairman's responsibilities, while other executives continue their roles normally [2]. - Lin Yanglin has been the chairman since March 2021, following the company's bankruptcy restructuring [4]. Group 2: Financial and Operational Overview - As of the end of 2024, Lin Yanglin holds 26 million shares of New Mileage, all of which are restricted stock [3]. - In 2024, New Mileage reported revenue of 3.8 billion yuan, a year-on-year decline of 2.95%, while net profit reached 115 million yuan, a significant increase of 296.13% [6]. - The company's core business focuses on medical services and pharmaceutical industry, with medical services accounting for nearly 80% of total revenue in 2024 [4][6]. Group 3: Business Strategy - New Mileage is advancing a regional medical center strategy, establishing a "1+N" innovative service model based on comprehensive hospitals and specialized branches, and a new elderly care model [5]. - The company plans to enhance its medical institutions and pharmaceutical enterprises' integration with its controlling shareholder's investment businesses, particularly focusing on the silver economy [6].

Core Viewpoint - New Mileage (002219.SZ) announced that its chairman, Lin Yanglin, is under investigation by the Taiyuan Municipal Xiaodian District Supervisory Committee, which has led to his inability to perform his duties, although the matter is unrelated to the company [1][3] Company Governance and Management - The company has appointed director Xu Minggui to act as chairman during Lin Yanglin's absence, as per the company's articles of association [1] - New Mileage emphasizes its robust governance and internal control mechanisms, stating that other board members and senior management are functioning normally, and the company's operations remain unaffected [3] Business Strategy and Performance - Lin Yanglin has been instrumental in proposing a "comprehensive hospital + specialized branch" chain model to strengthen regional medical center layouts, with 24 hospitals established across six major regions by 2024 [2][4] - The company reported a revenue of 796 million yuan in Q1 2025, a year-on-year decline of 16.49%, and a net profit of 25.65 million yuan, down 9.35% year-on-year [3] - New Mileage's net profit saw a significant drop of 80.29% in 2023, followed by a nearly 300% increase in 2024, indicating substantial performance volatility [3] Company Background - New Mileage, originally known as Hengkang Medical Group, was listed on the A-share market in March 2008 and has transitioned from a traditional Chinese medicine manufacturer to a comprehensive healthcare group [3][4] - The company currently operates three tertiary hospitals and 14 secondary hospitals, with nearly 10,000 beds across its facilities [4]

Group 1 - The core issue of retaining young medical talent after their training remains unresolved, despite various incentives such as tuition waivers and financial subsidies [1] - The "public-funded medical students" program is gaining attention, with local health commissions offering substantial financial incentives to attract medical talent back to their hometowns [1][2] - The service requirements for "public-funded medical students" typically mandate a return to their hometown for a minimum of six years post-graduation, raising concerns about job satisfaction and career development opportunities in rural areas [1][7] Group 2 - Two top counties in Jiangsu, Suzhou, are implementing targeted funding programs for high-achieving medical students, with financial support based on academic performance and a commitment to work in local healthcare for six to ten years [2][5] - The funding plans in Taicang and Zhangjiagang focus on specific medical specialties, with substantial financial support provided to students, including one-time grants and housing subsidies [5][6] - The local governments are responding to the "siphoning effect" of nearby major cities by enhancing their healthcare resources and attracting medical talent to prevent further loss of skilled professionals [3][4] Group 3 - The national landscape for "public-funded medical students" shows a predominance of programs aimed at training general practitioners for rural areas, with a limited focus on high-level talent [6][9] - Recent policy changes in some regions, such as Anhui and Guangdong, allow for greater flexibility in the career paths of directed medical students, including opportunities for further education and job mobility [8][9] - Despite high enrollment rates for directed medical students, retention in rural healthcare settings remains a challenge, with only about 8% of graduates staying in their assigned positions after their service period [9]

证券代码：002219 证券简称：新里程 新里程健康科技集团股份有限公司 投资者关系活动记录表 编号：2025-04 投资者关系 活动类别 特定对象调研 □ 分析师会议 □ 媒体采访 □ 业绩说明会 □ 新闻发布会 □ 路演活动 □ 现场参观 □ 其他 参与单位名称 （排名不分先后） 天风证券、中信建投、中信证券、首创证券、国投证券、申万宏源、 华鑫证券、中邮证券、国海证券、湘财证券、甬兴证券、东吴证券、 国泰海通证券、平安证券、信达证券、华安证券、国联民生证券、 招商证券、西南证券、东北证券、华福证券、国盛证券、国信证券、 国金证券、光大证券、方正证券、东方证券、华创证券、山西证券、 开源证券、德邦证券、东海证券、东方财富证券、华龙证券、五矿 金通、德恒国际、国科九合、国泰基金、浦银安盛基金、华夏基金、 南方基金、华富基金、朱雀基金、中海基金、天冶基金、方正富邦 基金、华泰保险、泰康资管、招商证券资管、国泰君安资管、中银 资管、欣歌投资、朴远资产、左道投资、上海禧弘私募基金、浙江 益恒投资、广东正圆投资、青骊投资、上海煜德投资、金百镕投资、 常春藤上海资管、大家资管等 时间 2025 年 7 月 4 日 地 ...

Investment Rating - The report maintains a strong confidence in the pharmaceutical sector, particularly in innovative drugs, predicting a reversal trend in 2025 [4] Core Viewpoints - The innovative drug sector is experiencing strong performance driven by multiple factors, including the completion of quarterly portfolio adjustments, increased policy support from the National Healthcare Security Administration (NHSA) and the National Health Commission, and significant collaborations in the industry [1][11] - The NHSA and the National Health Commission have jointly released measures to support the high-quality development of innovative drugs, which will accelerate the commercialization of domestic innovative products and create a positive cycle of profitability and strong R&D investment [20][21] - The report highlights the potential of dual/multi-target antibodies in cancer treatment and innovative drugs addressing unmet clinical needs in chronic diseases as key investment opportunities [1][4] Summary by Sections Innovative Drugs - The innovative drug sector remains the main investment line, with a focus on dual/multi-target antibodies for various cancers and chronic diseases [1][11] - AstraZeneca is in talks for a collaboration worth up to $15 billion for the AK112 drug, which has catalyzed strong performance in related stocks [1] Pharmaceutical Sector - The NHSA's new measures will direct more healthcare resources towards innovative drugs, enhancing their commercialization and profitability [20][21] - The report notes that since 2018, 149 innovative drugs have been included in the healthcare insurance directory, significantly increasing the proportion of new drugs covered [22] Biologics - Changchun High-tech's new drug, Vuxin Qibai monoclonal antibody, has been approved for treating acute gout arthritis, marking a significant advancement in biologics [29][34] - The drug shows rapid onset of action and a substantial reduction in recurrence risk, highlighting its clinical significance [33][34] Traditional Chinese Medicine - Lingrui Pharmaceutical's new indication for its nasal spray is expected to boost sales, with ongoing efforts to expand hospital coverage and OTC sales [38][41] Medical Devices - The report emphasizes policy support for high-end medical devices, predicting accelerated commercialization in various segments such as medical robots and AI [3][4] Medical Services - Recent policies to enhance maternity benefits are expected to stimulate demand in related services [3][4]